NATCO Pharma announced that Fresenius Kabi USA, LLC and Fresenius Kabi Deutschland GmbH (together, Fresenius) have filed a complaint against Natco Pharma USA LLC f/k/a Dash Pharmaceuticals LLC in the District Court of Delaware relating to the marketing of Dash Pharmaceuticals Diazepam Injection prefilled syringe in the United States.
Fresenius has not yet effectuated service of the complaint which is required to commence the lawsuit.
Natco Pharma intends to defend the matter accordingly.
Dash Pharmaceuticals LLC had been acquired by Natco Pharma, Inc. and Dash Pharmaceuticals LLC had changed its name to Natco Pharma USA LLC
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app